Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pmrj.2016.07.204 | DOI Listing |
Int Immunopharmacol
November 2024
School of Medicine, Southeast University, Nanjing 210000, China; Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China; Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Nanjing Medical School, Nanjing 210002, China; Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Southeast University, Nanjing 210002, China. Electronic address:
Background: A minority of patients with extensive-stage small cell lung cancer (ES-SCLC) exhibit prolonged survival following first-line chemoimmunotherapy, which warrants the use of reliable biomarkers. Here, we investigated the disparities in genomics and immune cell spatial distribution between long- and short-term survival of patients with ES-SCLC.
Methods: We retrospectively recruited 11 long-term (>2 years) and 13 short-term (<9 months) ES-SCLC survivors receiving first-line chemoimmunotherapy.
BMJ Open
July 2024
Department of Pulmonary and Critical Care Medicine, Xi'an Jiaotong University Medical College First Affiliated Hospital, Xi'an, China
Objective: The objective of this systematic review was to explore the evidence regarding shared decision-making (SDM) in the management of pulmonary nodules.
Design: Systematic review of quantitative and qualitative studies.
Data Source: Studies published in English or Chinese up to April 2022 were extracted from nine databases: PubMed, PsycINFO, EMBASE, Cochrane Library, Web of Science and CINAHL, China National Knowledge Infrastructure, Wanfang Data and SinoMed Data.
JACC CardioOncol
April 2024
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Background: The use of an artificial intelligence electrocardiography (AI-ECG) algorithm has demonstrated its reliability in predicting the risk of atrial fibrillation (AF) within the general population.
Objectives: This study aimed to determine the effectiveness of the AI-ECG score in identifying patients with chronic lymphocytic leukemia (CLL) who are at high risk of developing AF.
Methods: We estimated the probability of AF based on AI-ECG among patients with CLL extracted from the Mayo Clinic CLL database.
Med Dosim
November 2024
Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW 2145, Australia; Sydney Medical School, C24-Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia; Westmead Breast Cancer Institute, Westmead Hospital, Sydney, New South Wales, Australia. Electronic address:
To determine whether deep inspiratory breath-hold (DIBH) reduces dose to organs-at-risk (OAR), in particular the right coronary artery (RCA), in women with breast cancer requiring right-sided post-mastectomy radiotherapy (PMRT) including internal mammary chain (+IMC) radiotherapy (RT). Fourteen consecutive women requiring right-sided PMRT + IMC were retrospectively identified. Nodal delineation was in accordance with European Society for Radiology and Oncology (ESTRO) guidelines and tangential chest wall fields marked.
View Article and Find Full Text PDFInsights Imaging
March 2024
Department of Urology, the Fuyang Hospital of Anhui Medical University, Yingzhou District, No. 99, Mount Huangshan Road, Fuhe Modern Industrial Park, Fuyang, Anhui Province, 236000, People's Republic of China.
Objectives: To analyze the correlation among the imaging features of prostate "nodule in nodule," clinical prostate indices, and pathology results.
Methods: We retrospectively analyzed the prostate images from 47 male patients who underwent MRI scans and pathological biopsy from January 2022 to July 2023. Two radiologists (R1/R2) evaluated the morphology and signal intensity of the "nodule in nodule" in a double-blind manner and calculated the PI-RADS v2.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!